Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in…

November 2, 2010 By Bio-Medicine.Org

BASKING RIDGE, N.J., Nov. 2, 2010 /PRNewswire/ — Regado
Biosciences, Inc., a privately held company leading the development
of antithrombotic aptamers with active control agents, announced
that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President
and Chief Medical Officer, presented an abstract at the American
College of Chest Physicians (ACCP) Coagulation and Heart Disease
Sessions on November 2, 2010 in Vancouver, BC, Canada.  The
abstract is titled “Sustained Inhibition of Factor IXa by
Subcutaneous RB006 with Active Reversal: First-in-Human Experience
with the REG2 System.”

The REG2 system is intended for use in venous thrombosis
indications.  This initial Phase 1 study was the first
successful subcutaneous application of an aptamer in humans.
 It demonstrated that a single subcutaneous injection of RB006
(aka pegnivacogin) resulted in dose-dependent inhibition of Factor
IXa with effects that persisted longer than one week after
injection. The data is promising for future development of
REG2.

The abstract is coauthored by Steven L. Zelenkofske, D.O.,
Christopher P. Rusconi, Ph.D. and Carolyn M. Darmiento, MS, all
from Regado Biosciences; and Richard C. Becker, MD, Duke University
School of Medicine, Durham, NC and William Wargin, Ph.D., President
of PK-PM Associates, LLC.  

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private
biopharmaceutical company pioneering a new therapeutic technology
with the creation and development of proprietary controllable
aptamer drug systems.  Each system comprises a
nuclease-stabilized RNA aptamer, the therapeutic effect of which
can be reversed partially or completely in real time by its
specific and complementary oligonucleotide active control agent.
This technology is being applied to injectable antithrombotics
(including anticoagulants and antiplatelet agents) in the acute and
sub-acute care cardiovascular setting, a multi-billion dollar
world-wide market i

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech